The changes of prostate specific antigen (PSA) after treatment with alpha 1-adorenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level - A study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer

Acta Urologica Japonica

Volumn 55, Issue 4, 2009, Pages 187-191

  Hanai, Tadashi ^a,b,d,e   Matsumoto, Seiji ^a,e   Shouji, Sunao ^b   Usui, Yukio ^b   Tang, Xian Yan ^c   Kato, Yoshinari ^d   Iguchi, Masanori ^d   Uemura, Hirotsugu ^e   Terachi, Toshirou ^b  

^a Urological and Urodynamics Center   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY   (Japan)

^d Kaizuka City Hospital   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha 1 adrenergic receptor antagonists (alpha 1 blockers); Benign prostatic hyperplasia lower urinary tract symptom (BPH LUTS); Prostate specific antigen (PSA)

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; SULFONAMIDE; TAMSULOSIN;

AGED; ARTICLE; COMPARATIVE STUDY; HUMAN; MALE; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SULFONAMIDES; URINARY RETENTION;

EID: 66249149031     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wright EJ, Fang J, Metter EJ, et al.: Prostate specific antigen predicts the long-term risk of prostate enlargement ; results from the Baltimore longitudinal study of Aging. J Urol 167 : 2484-2487, 2002
2. Nadler RB, Collins MM, Propert KJ, et al.: Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pain syndrome. Urology 67 : 337-342, 2006
3. Debruyne F, Koch G, Boyle P, et al.: Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia : a 1-year randomized international study. Eur Urol 41: 497-506, 2002
4. Kurita Y, Masuda H, Suzuki K, et al.; Transition zone ratio and prostate-specific antigen density as predictors of response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Br J Urol 80 : 78-83, 1997
5. 1-Blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction : what are the relevant differences in randomized controlled trials ? Eur Urol 38: 25-39, 2000
6. Bartsch G, Fitzpatrick JM, Schalken JA, et al.: Consensus statement : the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 93 : 27-29, 2004
7. Roehrborn CG : Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention : results of a 2-year placebo-controlled study. BJU Int 97 : 734-741, 2006
8. Marberger M : The MTOPS Study : new findings, new insights and clinical implications for the management of BPH. Eur Urol 5 : 628-633, 2006
9. van Renterghem K, Van Koeveringe G, Achten R, et al.: Clinical relevance of transurethral resection of the prostate in "Asymptomatic" patients with an elevated prostate-specific antigen level. Eur Urol 52: 819-826, 2007
10. Laniado ME, OckrimJL, Marronaro A, et al.: Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 94: 1283-1286, 2004
11. Tubaro A and La Vecchia C ; Uroscreening Study Group : The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction : an Italian survey. Eur Urol 45 : 767-772, 2004
12. Van Renterghem K, Van Koeveringe G and Van Kerrebroeck P: Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link? Int Urol Nephrol 39: 1107-1113, 2007